Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Acquisitions & Divestments (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Change in Acquisitions & Divestments for 14 consecutive years, with $101.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 30.68% year-over-year to $101.5 million, compared with a TTM value of $286.7 million through Dec 2025, down 12.22%, and an annual FY2025 reading of $262.9 million, down 31.45% over the prior year.
  • Change in Acquisitions & Divestments was $101.5 million for Q4 2025 at Enanta Pharmaceuticals, up from $72.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $134.5 million in Q4 2023 and bottomed at $26.7 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $78.1 million, with a median of $75.0 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 210.73% in 2023, then crashed 76.51% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $108.8 million in 2021, then dropped by 4.29% to $104.1 million in 2022, then increased by 29.22% to $134.5 million in 2023, then crashed by 42.28% to $77.6 million in 2024, then soared by 30.68% to $101.5 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ENTA at $101.5 million in Q4 2025, $72.4 million in Q3 2025, and $59.7 million in Q2 2025.